Frontlight ResearchEarly access
Trial site
MVZ GynKrefeld GmbH
- 5running trials
The trials here
What the 5 trials at this site are about, from their registry records.
- Conditions
- Metastatic breast cancer2 trials
- Ovarian cancer1 trial
- Triple-negative breast cancer1 trial
- Phase
- Phase 33 trials
- Phase 22 trials
- Status
- Recruiting3 trials
- Active, not recruiting2 trials
- Lead sponsor
- AGO Research GmbH2 trials
- Gilead Sciences1 trial
- Olema Pharmaceuticals, Inc.1 trial
- Relay Therapeutics, Inc.1 trial
Running trials
Recruiting
Recruiting
Active, not recruiting
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Recruiting
Active, not recruiting
Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Metastatic breast cancer1 recruiting
- Triple-negative breast cancer1 recruiting
Site data: EU CTIS (euclinicaltrials.eu)Updated 17 Nov 2026